Wyeth Antibiotic Tygacil Approved For Broad-Spectrum, Early Use

Tigecycline, a first-in-class antibiotic, receives approval June 15 after a six-month priority review. Wyeth is highlighting Tygacil's broad-spectrum efficacy and potential as an empiric monotherapy. The application was based on two trials in complicated skin and skin structure infections and two trials in complicated intra-abdominal infections.